Carbamazepine belongs to the class II biopharmaceutical classifi cation system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. e bioavailability of such a drug is limited by the dissolution rate. e present study deals with the formulations of immediate release tablets of poorly soluble carbamazepine. As model tablets for this investigation, two formulations (named "A" and "B" formulations) of carbamazepine tablets labeled to contain  mg were evaluated. e aim of this study was to establish possible diff erences in dissolution profi le of these two formulations purchased from the local market.
Introduction
Carbamazepine is a dibenzazepine derivative with antiepileptic and psychotropic properties. It is also used in the treatment of trigeminal neuralgia and pain associated with other neurological disorders () . It belongs to Class II biopharmaceutical classifi cation system (BCS) which is characterized by high membrane permeability, slow dissolution rate due to low aqueous solubility, and high peroral dose () . e rate of oral absorption of poorly soluble drugs is often controlled by their dissolution rate in the gastrointestinal tract. erefore, bioavailability rate of this drug is limited by the dissolution rate () .
us solubility and dissolution rate are the key determinants of oral bioavailability, which is the concluding point drawn for fate of oral bioavailability (,) . Carbamazepine is a widely prescribed antiepileptic drug having poor water solubility (~ mg/l at  o C) () . The plasma half-life ranges from  to  hours following a single dose and from  to  hours during chronic therapy. Because of having poor water solubility, its absorption is dissolution rate limited, which often results in irregular and delayed absorption () . Several attempts have been made to increase the dissolution rate or bioavailability of carbamazepine (-) . Different methods have been exploited to enhance the dissolution of poorly water soluble drugs among which solid dispersion (SD) techniques, because of their simplicity and effectiveness have received considerable attentions () . e aim of this study was: -to compare two formulations (named "A" and "B" formulations) of carbamazepine tablets labelled to contain  mg, purchased from the local market; -to establish possible differences in dissolution profile of these two formulations.
Material and Methods

Reagents
The used reagents carbamazepine and sodium lauryl sulphate were of analytical grade and were provided by Sigma-Aldrich, St. Louis, USA, and by Merck, Darmstadt, Germany, respectively.
Tablet composition and preliminary comparison Two formulations ("A" and "B") contained  mg of active substance, and excipients, as follows ( C. e test was provided using Pharma Test disintegration tester Type PTZ-E /E (Pharma Test, Hainburg, Germany). Disintegration time for both formulations indicated that there was no signifi cant diff erence between products-the tablets were disintegrated in less than  minutes (according to USP, up to  minutes). In accordance with the USP monograph for carbamazepine tablets (declared strength  mg), the rate of dissolution was determined for two products formulations ("A" and "B").
Dissolution test conditions and analysis procedure Preparation of standard solutions A standard curve of absorbance versus concentration was constructed using solutions of carbamazepine in the dissolution medium (water containing  sodium lauryl sulphate) ranging in concentration from , to , mg/ml. Absorbance versus concentration plot (y=,x+,; R= ,) was linear over this concentration range and was used to determine percent of drug dissolved in the dissolution experiments. UV absorbance of each standard solution was measured spectrophotometrically at  nm.
Dissolution test procedure
e dissolution tests of carbamazepine tablets (formulation "A" and "B") were performed using USP apparatus  (n=), ERWEKA DT  dissolution tester. e amount of drug in the tablet was  mg (declared strength) which was added to  ml of distilled water containing  sodium lauryl sulphate as dissolution medium. Under such circumstances a perfect sink condition was maintained to mimic the dynamic situation in GI tract. e mixture was stirred at  rpm at ±, o C. Samples in the amount of  ml were withdrawn at predetermined times (th and th min), fi ltered and assayed at  nm spectrophotometrically. The drug concentration in the samples was corrected mathematically (correction for volume), considering the concentrations of the previous samples (withdrawn samples were not supplemented with an equal volume of fresh dissolution fl uid to maintain a constant total volume). e dissolution apparatus was maintained at ±,°C throughout the experiment. Prior to use, the dissolution media were equilibrated at  o C for two hours and fi ltered using a , μm membrane fi lter (Sartorious GmbH, Goettingen, Germany) to deaerate the medium so that bubble formation during the test, due to escape of dissolved gases, was minimized. Dissolution samples were collected for analysis. ese samples were filtered using a , μm membrane filter (Sartorious GmbH, Goettingen, Germany). e dissolution apparatus was connected with UV/VIS spectrophotometer Shimadzu UV- (Shimadzu, Kyoto, Japan). Determination of dissolution rates for the active ingredient in tablets (formulations "A" and "B") is carried out by the previously mentioned spectrophotometric method.
Results and Discussion
During dissolution testing, by visual examination, diff erent behaviour of disintegrated, dispersed particles in dissolution medium (see Figures  and ) can be noticed:
• Formulaton "A": disintegrated fine particles are evenly dispersed in dissolution medium, without the presence of large agglomerates (Figure a, b and c):
• formulation B: disintegrated particles bind together into larger agglomerates, which were formed at the bottoms of dissolution vessels, could be seen on the Figures a, b and c. is occurrence resulted in decreased dissolution surface, decreased stirring rate infl uence of dissolution medium and, consequently, lower results than those specifi ed USP monograph:
e results of dissolution studies for "A" and "B" formulations are summarized in Table ., Table  ., which show the fraction of the dissolved drug as a function of time.
According to the USP -NF , ˝ release of carbamazepine from tablets (labelled strength  mg) fulfilled requirements if: between  and  of the labeled amount of carbamazepine was dissolved in  minutes; not less than  (Q) of the declared con- tents was dissolved for a period of  minutes (stage I). Fractions of carbamazepine released in dissolution medium were calculated from calibration curve.
In our study, in vitro release of carbamazepine from: -"A" formulation fulfilled these requirements (obtained release profile: , -,  and , -, , in  and  minutes, respectively); -"B" formulation did not fulfil these requirements (obtained release profi le: , -,  and , -, , in  and  minutes, respectively). 
Conclusion
-regardless of similar composition of two tablet formulations, it could be assumed that the technological process of tablet production signifi cantly aff ected dissolution rate; -disintegration time could not be considered as a discriminatory test that would be able to point out the diff erences in the dissolution rate, due to the very short disintegration time for both formulations (≤  minutes); -inter-agglomeration of particles dispersed in dissolution medium could signifi cantly reduce dissolution rate of carbamazepine tablets; -visual examination that, eventually, could be able to confi rm formation of agglomerate, during the dissolution test performed ( as it was shown for tablet formulation "B" -Figure a, b and c), could point out the fl aws in the development of tablets and point out to possible diffi culties in the dissolution rate of the investigated products.
